1. Home
  2. ENHA vs AARD Comparison

ENHA vs AARD Comparison

Compare ENHA & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enhanced Group Inc. Class A Common Stock

ENHA

Enhanced Group Inc. Class A Common Stock

N/A

Current Price

$7.10

Market Cap

114.5M

ML Signal

N/A

Logo Aardvark Therapeutics Inc.

AARD

Aardvark Therapeutics Inc.

N/A

Current Price

$1.00

Market Cap

97.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ENHA
AARD
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
114.5M
97.4M
IPO Year
2025
2025

Fundamental Metrics

Financial Performance
Metric
ENHA
AARD
Price
$7.10
$1.00
Analyst Decision
Strong Buy
Hold
Analyst Count
3
11
Target Price
★ $22.33
$4.00
AVG Volume (30 Days)
211.6K
★ 1.2M
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 43.11
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$118.94
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$0.93
52 Week High
$14.09
$16.60

Technical Indicators

Market Signals
Indicator
ENHA
AARD
Relative Strength Index (RSI) 57.45 29.19
Support Level $6.30 N/A
Resistance Level $14.09 $5.78
Average True Range (ATR) 1.29 0.20
MACD -0.25 0.10
Stochastic Oscillator 32.89 11.82

Price Performance

Historical Comparison
ENHA
AARD

About ENHA Enhanced Group Inc. Class A Common Stock

Enhanced Group Inc develops and sells sports and performance-related products intended for use by athletes and consumers. Its offerings focus on products associated with physical performance, health, and recovery. Its two principal offerings include: (i) the Enhanced Games, a live, multi-sport competition platform designed to showcase both "Enhanced" and "Non-Enhanced" athletes pursuing world-record performances under medically supervised conditions; and (ii) Live Enhanced, a direct-to-consumer digital and clinician-guided wellness platform offering evidence-based protocols, supplements, and coaching for consumers seeking to improve health, longevity, and well-being. The majority of the company's revenue is derived from products associated with physical performance, health, and recovery.

About AARD Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Share on Social Networks: